Stock Market News2 weeks Danaher Gears Up to Post Q4 Earnings: What Lies Ahead for the Stock? Zacks
DHR’s Q4 results are likely to be ailed by weakness in the Biotechnology and Life Sciences segments.
XDHR’s Q4 results are likely to be ailed by weakness in the Biotechnology and Life Sciences segments.
X